FDA Releases Guidance to Promote Nonopioid Alternatives for Chronic Pain
New guidance aims to increase nonopioid choices for chronic pain while combating misuse
Half of Women With Hyperemesis Gravidarum Report Major Impacts on Life
Antiemetic use and outcomes vary widely for this group of patients
WHO Updates List of Essential Medicines to Include GLP-1s
PD-1/PD-L1 immunotherapies for several metastatic cancers also made the list of essential drugs
2000 to 2023 Saw Rise in Pediatric Exposure to Medications, Supplements
Overall rate of exposure for children aged 6 to 12 years up by 53.8 percent; >300 percent increase in exposure linked to self-harm, suicidal intent
One in 10 Undergoing Early Cancer Surgery Have New Persistent Opioid Use
Persons in the highest quartile of morphine milligram equivalents exposure have increased risk for new persistent opioid use
Baxdrostat Reduces Seated Systolic BP in Uncontrolled, Resistant Hypertension
Addition of baxdrostat to background therapy results in significantly lower seated systolic blood pressure
FDA Expands Use of Vonvendi for Von Willebrand Disease
The recombinant treatment is now approved for prophylactic use in adults and for treating bleeding episodes and perioperative use in children
Many Preschoolers Receive ADHD Medications Within 30 Days of Diagnosis
Asian, Hispanic, and Black children less likely to be prescribed medication early compared with White children
FDA Creates ‘Green List’ of GLP-1 Drug Ingredients Approved for Entry in the U.S.
The purpose of the list is to keep unverified and unapproved GLP-1 drug ingredients from entering the country
Industry Payments Common Among Neurologists Prescribing MS Drugs
Nearly 80 percent of neurologists received payments; higher prescription volumes linked to higher receipt of payments
